Non-Invasive Indirect Markers of Liver Fibrosis after Interferon-Free Treatment for Hepatitis C.
3D regimen
HCV eradication
hepatitis C
non-invasive fibrosis markers
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
31 Aug 2021
31 Aug 2021
Historique:
received:
14
07
2021
revised:
26
08
2021
accepted:
28
08
2021
entrez:
10
9
2021
pubmed:
11
9
2021
medline:
11
9
2021
Statut:
epublish
Résumé
The effectiveness of interferon-free therapy during the course of HCV infection has already been confirmed. Liver fibrosis can be assessed in several ways, from biopsies to imaging tests. The present study evaluates the usefulness of non-invasive indirect biomarkers of liver fibrosis (APRI, GAPRI, FORNS, FIB-4, the AP index and HUI score) as markers of the effective treatment of HCV with the 3D regimen. Blood samples were collected from 70 patients suffering from chronic hepatitis C. Patients received the 3D AbbVie regimen for hepatitis C. All patients had HCV genotype 1b. The APRI, GAPRI, FIB-4, FORNS, HUI and AP index (age-platelet score) values were calculated with their respective algorithms. The stage of fibrosis was evaluated on the basis of a liver biopsy and confirmed by FibroScan-based transient elastography. An undetectable level of HCV RNA after 12 weeks of treatment with the 3D regimen indicates 100% eradication of hepatitis C virus. After the treatment, non-invasive indirect markers of liver fibrosis achieved levels below the limit for significant fibrosis, Thus, non-invasive indirect biomarkers of hepatic fibrosis failed to detect the presence of significant fibrosis, which was proved in histopathological examination. However, the eradication of hepatitis C virus by means of the 3D regimen treatment does not mean that patients were completely cured.
Identifiants
pubmed: 34501398
pii: jcm10173951
doi: 10.3390/jcm10173951
pmc: PMC8432198
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Hepatol. 2017 Oct;67(4):700-707
pubmed: 28645740
Ann Hepatol. 2018 Oct 16;17(6):959-968
pubmed: 30600291
J Hepatol. 2018 Aug;69(2):461-511
pubmed: 29650333
Clin Drug Investig. 2017 Nov;37(11):1009-1023
pubmed: 28871475
Hepatology. 2000 Sep;32(3):477-81
pubmed: 10960438
World J Gastroenterol. 2007 Aug 28;13(32):4287-94
pubmed: 17708599
Am J Gastroenterol. 2007 Nov;102(11):2589-600
pubmed: 17850410
Clin Chem. 2004 Aug;50(8):1344-55
pubmed: 15192028
BMC Gastroenterol. 2001;1:12
pubmed: 11707153
Am J Gastroenterol. 2005 Mar;100(3):616-23
pubmed: 15743360
Hepatol Commun. 2018 Oct 05;2(11):1311-1319
pubmed: 30411078
Comp Hepatol. 2012 Dec 28;11(1):5
pubmed: 23273224
Ultrasound Med Biol. 2003 Dec;29(12):1705-13
pubmed: 14698338
Clin Pharmacokinet. 2016 Mar;55(3):275-95
pubmed: 26330025
Turk J Gastroenterol. 2016 Mar;27(2):156-64
pubmed: 26853790
World J Hepatol. 2016 Jan 18;8(2):92-106
pubmed: 26807205
Hepatology. 2003 Aug;38(2):518-26
pubmed: 12883497
Hepatology. 2007 Jul;46(1):32-6
pubmed: 17567829
Transplant Proc. 2019 Sep;51(7):2397-2402
pubmed: 31402255
Hepatogastroenterology. 2009 Sep-Oct;56(94-95):1459-65
pubmed: 19950810
J Viral Hepat. 1997 May;4(3):199-208
pubmed: 9181529
Gut. 2008 Sep;57(9):1288-93
pubmed: 18448567
Hepatology. 2015 Sep;62(3):932-54
pubmed: 26111063
Hepatology. 2002 Oct;36(4 Pt 1):986-92
pubmed: 12297848